Recent advances in the management of Barrett ' s esophagus may kindle enthusiasm for screening for esophageal adenocarcinoma (EAC). Symptoms of gastroesophageal refl ux disease (GERD) are recognized as relative risks for EAC. However, the absolute incidence of EAC in specifi c populations with GERD is unknown. We aimed to estimate the symptom-, age-, and sex-specifi c incidences of EAC, and place these incidences in the perspective of other cancers for which screening is endorsed.
INTRODUCTION
Esophageal adenocarcinoma (EAC) is a particularly deadly neoplasm, and its incidence is rising rapidly ( 1, 2 ) . Symptoms of gastroesophageal refl ux disease (GERD) are a major risk factor for EAC ( 3 -7 ) . As an endoscopically recognizable precancerous lesion, Barrett ' s esophagus, is associated with EAC ( 8 ), some subspecialty guidelines have advocated endoscopic screening of patients with GERD in an attempt to reduce mortality from EAC ( 9 -11 ) . Other guidelines have tempered such recommendations, citing the lack of proven effi cacy of screening, and imprecision in estimating the risk of cancer in individual patients ( 12 -14 ) . Th e US Preventive Services Task Force has not published any guidelines for or against screening for EAC ( 15 ) . Nonetheless, a recent survey of practicing American gastroenterologists found that 98 % would recommend screening a 55-year-old man with long-standing frequent GERD, and substantial proportions would screen other groups of patients with GERD ( 16 ) . Recent advances in molecular and endoscopic markers predicting the risk of progression of Barrett ' s esophagus ( 17 -19 ) , and in the endoscopic treatment of neoplasia within Barrett ' s esophagus ( 20, 21 ) , will likely lead to greater enthusiasm for screening for EAC.
Esophageal Adenocarcinoma Incidence in Individuals
With Gastroesophageal Refl ux: Synthesis and Estimates From Population Studies Figure 1 . Markov model. The Markov model stratifi es the population into those with at least weekly gastroesophageal refl ux disease (GERD) symptoms and those without GERD symptoms (or less frequent symptoms). In each stratum, there is an annual chance of developing esophageal adenocarcinoma (EAC) and dying from other causes. Those alive without EAC at the end of a year cycle again through the model. The annual incidence of EAC in those with GERD is determined by applying the standardized incidence ratio to the incidence in the stratum without GERD. The incidence in the stratum without GERD is determined by calibrating the standardized incidence ratio in that group compared with the unstratifi ed population such that the summed incidence across strata is identical to the age-and sex-specifi c incidences obtained from SEER for the unstratifi ed population. The model and calibration is repeated for a threshold of daily GERD symptoms, and for each sex.
Th e US Institute of Medicine recently published a list of priorities for comparative-eff ectiveness research; within the top 25 priorities was to compare the eff ectiveness of upper endoscopy utilization in patients with GERD on the diagnosis of EAC ( 22 ) . In addition to knowledge regarding the effi cacy and adverse eff ects of a screening and endoscopic prevention strategy, assessing the net benefi ts of a screening strategy requires an understanding of the absolute risk of cancer in the screened population; in this case, patients with GERD. Although the relative risk of EAC is known to be increased by the presence of GERD, as well as by white race, male sex, and advancing age ( 14 ) , the absolute age-, sex-, and race-specifi c incidences of EAC in patients with GERD has never been described in detail. We aimed to fi ll that gap by creating a computer model to estimate the incidence of EAC. To place our fi ndings in context, we also compared the estimated absolute incidence of EAC with the observed incidence of colorectal and breast cancers, for which screening is recommended by the US Preventive Services Task Force ( 15 ) .
METHODS
Th e incidence of EAC in patients with GERD may be calculated using (i) the incidence in the baseline population (unstratifi ed for the presence of GERD), (ii) the prevalence of GERD, and (iii) the standardized incidence ratio in people with GERD compared with those without GERD (see Supplementary Material online). We therefore created a Markov computer model using these three parameters. We obtained the incidence in the baseline population directly from the US Surveillance Epidemiology and End Results (SEER) cancer registry, the prevalence of GERD symptoms from a published systematic review ( 23 ) , and the standardized incidence ratio in people with GERD compared with those without GERD from a meta-analysis of published studies ( 24 ) . Derivation of each parameter is detailed below. Th e study was exempted from review by the Institutional Review Board of the Ann Arbor Veterans Administration Medical Center.
Markov model of incidence of EAC
Using TreeAge Pro Suite 2009 soft ware (TreeAge Soft ware, Williamstown, MA), we created a Markov computer model of the development of EAC predicting the age-and sex-specifi c incidences of EAC in the general white non-Hispanic population, stratifi ed by the presence or absence of clinically relevant GERD, and accounting for competing age-, sex-, and race-specifi c risk of death from all other causes ( Figure 1 ) ( 25 ) . We fi rst defi ned GERD as occurring at least once weekly, and used the estimated standardized incidence ratio of EAC for men with weekly GERD compared with those without GERD or less frequent GERD. Th erefore, the absolute incidences in both strata depended on the standardized incidence ratio of EAC for men without GERD (or less frequent GERD) compared with the general male, unstratifi ed population. Th at standardized incidence ratio was calibrated such that the cumulative incidences of EAC in the Markov model summed across GERD strata was identical with the cumulative incidence of EAC expected in the general male white nonHispanic population from SEER. We found that this also resulted in identical sums of age-specifi c incidences across GERD strata, with the expected age-specifi c incidences in the general male population. Th e validation of the model is reported in the Supplementary Materials . Th e entire stratifi ed model was then repeated for females, as well as with a threshold of GERD occurring at least daily compared with no GERD or less frequent symptoms for each sex. Th e incidence rates estimated from the Markov model were applied to the standard US population from 2005 in order to estimate absolute age-, sex-, and GERD-specifi c counts of EAC cases ( 26 ) .
Data sources
Incidence of EAC . Th e US age-and sex-specifi c incidences of EAC for white non-Hispanics up to age 79 years were obtained using SEER * Stat soft ware v.6.4.4 (Th e Surveillance Research Program of the Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD and Information Management Services, Silver Spring, MD) for the years 2000 -2005, using an electronically available dataset from the SEER cancer registry ( 27 ) . Th e set of International Classifi cation of Diseases for Oncology, Th ird Edition codes used for EAC were 8140 -8575, with a site of the esophagus. In situ cancers were excluded.
Standardized incidence ratio of GERD for EAC
. Th e standardized incidence ratio of GERD for EAC was estimated from the random eff ects summary odds ratio of GERD symptoms for EAC from population-based studies with strict ascertainment of exposure and outcomes ( 24 ) . For weekly GERD vs. less frequent or no GERD, the standardized incidence ratio was 4.92 (95 % confidence interval = 3.90, 6.22). For daily GERD vs. less frequent or no GERD, the standardized incidence ratio was 5.53 (95 % confi dence interval = 4.00, 7.65).
Prevalence of gastroesophageal refl ux symptoms . Weekly GERD : A recently published systematic review of the prevalence of weekly GERD concluded that the prevalence has been rising in the United States by a 5 % relative rate annually ( 23 ) . Our base case prevalence of weekly GERD was therefore the most recently published estimate in a white population in the United States (28.2 % from a study published in 2004) ( 28 ) . In sensitivity analysis, the upper limit utilized was the 95 % upper confi dence limit from that study (35.0 % ). Th e lower limit was the minimum of the prevalence found in that systematic review and in the control populations of the two American studies in the meta-analysis of GERD symptoms and EAC risk ( 24 ) , which resulted in a lower confidence limit of 11.6 % ( 4 ).
Daily GERD : Th e published survey studies of the prevalence of GERD in the United States do not report the prevalence of daily symptoms. Instead, we used the weighted mean prevalence in the control populations of the two American studies in the metaanalysis of GERD symptoms and EAC risk (6.7 % ) ( 4, 5 ) . Since the symptoms reported in those two studies occurred around 1993, we applied a 5 % annual increase ( 23 ) to estimate the prevalence in 2004 (the same year used in the base case for weekly GERD) at 11.5 % . In the sensitivity analysis, the upper limit utilized the 95 % upper confi dence limit of the weighted mean prevalence (7.9 % ), and applied the 95 % upper confi dence limit of the annual increase in GERD (7.9 % ) ( 23 ), resulting in an upper estimate of daily GERD of 18.2 % in 2004. Th e lower limit was directly obtained from the minimum of the estimates from the two American studies (6.0 % ).
Sensitivity analysis
Th e upper and lower confi dence limits of the incidences of EAC in GERD were identifi ed by simultaneously varying the prevalence of GERD and standardized incidence ratio of GERD for EAC, repeating this for each sex, and for both weekly and daily symptoms. Th e upper limit incidence scenario incorporated the upper limit of the standardized incidence ratio and the lower limit of the prevalence of GERD. Th e lower limit incidence scenario incorporated the lower limit of the standardized incidence ratio and the upper limit of the prevalence of GERD.
Comparisons to other cancers
In order to contextualize the symptom-specifi c incidence of EAC, we compared it with the age-and sex-specifi c incidences of colorectal and breast cancers in white non-Hispanics (unstratifi ed with regards to GERD symptoms), because of the acceptance of screening for those cancers ( 15 ) . Th e incidences of these cancers were obtained from the identical SEER data set from the identical time frame as the EAC incidence. We defi ned a benchmark as the minimum age-and sex-specifi c incidences of cancer at which screening has been endorsed for colorectal (incidence at the age of 50 years) or breast cancer (incidence at the age of 40 years) ( 15, 29 ) . As the current study does not assess the eff ectiveness of screening or the cost of such a policy, the data cannot support positive statements about which, if any, populations should be screened for EAC. Rather, by estimating the symptom-specifi c incidence of EAC, and comparing it to the incidence of cancers for which screening is believed to be eff ective and is endorsed, the data can support negative statements about which populations should not be screened, if the incidence of EAC in that population falls below the minimum incidences of colorectal or breast cancer for which screening is off ered.
Outcomes
Th e primary outcomes of the study were the age-and sex-specifi c incidences of EAC in individuals with weekly or daily GERD symptoms. Th e secondary outcomes included the ages at which the incidence of EAC exceeded the benchmark minimum incidence of breast or colorectal cancer for which screening is endorsed. Another secondary outcome was the proportion of EAC arising from patients whose expected risk was greater than that benchmark.
RESULTS

Incidence of EAC with weekly GERD symptoms
Th e incidence of EAC in women with weekly GERD was quite low at any age ( Figure 2 ; Supplementary Table 1 ). For example, at 60 years, women with weekly GERD had an EAC incidence of 3.9 / 100,000 person-years. Furthermore, the EAC incidence in men without weekly GERD was greater than the EAC incidence in women with GERD at any age ( Supplementary Table 1 ) . Th e incidence of EAC in men with weekly GERD may be considered substantial over the age of 60 years. For example, at 70 years, such men are expected to have an annual incidence of EAC of 60.8 / 100,000. Th e incidences of EAC in men and women with daily GERD symptoms were only slightly greater than those with at least weekly symptoms ( Figure 3 ; Supplementary Table 1 ).
Comparison to other cancers
At the ages that screening for cancer has been endorsed to commence in the United States, the incidence of breast cancer in women was 100.5 / 100,000 cases at the age of 40 years, the incidence of colorectal cancer in men was 47.2 / 100,000 at the age of 50 years, and the incidence of colorectal cancer in women was 35.6 / 100,000 at the age of 50 years. Th erefore, we defi ned the benchmark incidence of cancer below which screening has not been recommended despite the availability of eff ective screening modalities, and this was found to be 35.6 / 100,000.
Th e incidence of EAC in women with weekly GERD was not expected to breach the benchmark incidence for screening at any age ( Figure 2 ; Supplementary Table 1 ). For instance, at the age of 50 years, the incidence of EAC in a woman with GERD is expected to be an order of magnitude lower than her incidence of colorectal cancer. In fact, women with weekly GERD have a similar incidence ESOPHAGUS Esophageal Adenocarcinoma Incidence in GERD of EAC as the incidence of breast cancer in men. Men with weekly GERD were expected to exceed the benchmark incidence at 61 years ( Figure 2 ; Supplementary Table 1 ). However, at any age, the incidence of colorectal cancer was at least three times greater than the expected incidence of EAC in men with weekly GERD. For example, at the age of 70 years, men with weekly GERD had an expected incidence of EAC of 60.8 / 100,000 and an incidence of colorectal cancer of 265.6 / 100,000. Th is relative risk of colo rectal cancer was even greater at younger ages. At 35 years, men with weekly GERD had an expected incidence of colorectal cancer that was 6.7 times that their expected incidence of EAC. In sensitivity analysis, men with weekly GERD breached the benchmark incidence between ages 55 and 64 years. Even in the upper limit sensitivity analysis, the incidence in women of any age did not exceed the benchmark.
In individuals with daily GERD symptoms, at all ages the incidence of EAC in women was lower than the benchmark incidence, including in sensitivity analyses ( Figure 3 ; Supplementary Table 1 ). Men with daily GERD were expected to exceed the benchmark at the age of 55 years, and in sensitivity analyses, it ranged from ages 52 to 59 years ( Figure 3 ; Supplementary  Table 1 ).
Proportions of EAC cases arising from specifi c groups
Applying the incidences from the base case analysis to the US standard population from 2005 produced absolute counts of EAC cases. Among white non-Hispanics younger than the age of 80 years, there were 5,920 cases of EAC in 2005. Th e proportion of EAC cases arising from specifi c groups is shown in Figure 4 . Men with weekly GERD > 60 years of age account for 36 % of these EAC cases. Women account for only 12 % of EAC cases, including all ages and regardless of GERD. Individuals without weekly GERD account for 34 % of EAC cases. Men aged 55 -60 years with daily GERD accounted for 7 % of EAC cases (a stratum not shown in Figure 4 ).
DISCUSSION
We synthesized data from multiple sources to estimate the age-, sex-, and symptom-specifi c incidences of EAC, and compared these incidences with those of cancers for which screening is recommended. A number of important observations arise from this study. First, we conclude that women of any age with GERD have a very low risk of developing EAC. Th is is due to the exceedingly low baseline incidence of EAC among women. Second, we conclude that the risk of EAC in men with GERD younger than 61 years (or younger than 55 years if GERD occurs daily) is relatively low; people with a similar risk for colorectal or breast cancer are not off ered screening despite the accepted eff ectiveness of screening for those cancers. If we are to recommend screening for EAC among these younger men with GERD, then we should likewise be prepared to recommend average risk people younger than 50 years to undergo colon cancer screening. Finally, we conclude that the incidence of EAC is substantial in white men with at least weekly GERD who are above the age of 60 years, and in white men with at least daily GERD who are at least 55 years of age. Screening for EAC in these groups of men might be reasonable if the practice were eff ective; however, there is no high-quality evidence to support the contention that screening is eff ective for reducing mortality from EAC ( 13,14,30 -34 ) . Furthermore, the risk of colorectal cancer in these men is expected to be at least three times greater than their risk of EAC. Th erefore, the highest yielding screening test in a 65-year-old man with GERD is one for colon cancer, not a test for EAC as many providers and patients may believe. Th ese fi ndings contrast with the results of a survey of practicing American gastroenterologists ( 16 ) . In that survey, 73 % reported they would recommend screening for a 35-year-old man with GERD, but the current study estimates that such a patient has a risk of colorectal cancer that is over fi vefold greater than his risk of EAC, and yet the patient would be very unlikely to be off ered colorectal cancer screening. In the same survey, 42 % of gastroenterologists would recommend screening for a 55-year-old woman with GERD, but the current study estimates that her risk of EAC is similar to a man ' s risk of developing breast cancer -not zero, but exceedingly small. Finally, the survey found that 16 % would recommend screening for a 35-year-old woman with GERD; the current study estimates that her annual incidence of EAC is less than 1 per 1 million. Th ose providers ' recommendations are likely in part due to too much attention assigned to the relative risk of GERD and too little to the baseline incidence of EAC ( 35 ) . We hope that the current study can assist providers in recognizing the absolute risk of EAC in individual patients with GERD within the context of the risk of other more familiar cancers, and enable them to communicate these risks to patients to guide them in making rational decisions against screening for EAC.
Paradoxically, we found that despite the substantial incidence of EAC in older men with GERD, they only account for 43 % of all EAC cases presenting under the age of 80 years. Th erefore, any screening program directed at older men with GERD would be destined to have limited impact on reducing the mortality burden from this cancer, regardless of the effi cacy of screening and patient and provider adherence to the screening program. A screening program might be applied to wider populations such as women or younger men with GERD, but the incremental resource utilization required to screen those populations would be in great excess to the incremental benefi t. Th e conundrum might be resolved if additional factors were identifi ed that could further stratify risk for EAC among the lower risk groups (women and younger men with GERD, or older men without GERD) and were incorporated in the model. Candidate factors would include obesity and tobacco use ( 7 ), but incorporating them would require detailed recent data regarding the covariance of GERD, obesity, and tobacco use in Western populations.
To our knowledge, the only prior study on this topic was a letter describing the absolute incidence of EAC in the Swedish population limited to overweight men with GERD over the age of 50 years, and it did not provide the age-specifi c incidence ( 36 ) . Th e current study estimates age-specifi c incidences for both American men and American women with GERD. We utilized a recursive Markov model design to estimate these incidences, validated by comparing the predicted age-specifi c incidence in the general population to that observed in two countries, and compared the predicted symptom-specifi c incidences with those predicted by a static mathematical model. We fi nd that these redundant methods of validation are re-assuring.
Nonetheless, the current study is limited by available data. Although the fi rst population-based study estimating the eff ect of duration of GERD symptoms on the incidence of EAC found a dramatic threshold eff ect at 20 years duration, the subsequent studies have found little or no eff ect of longer duration beyond the eff ect of frequency of GERD symptoms ( 3 -7 ) . Because of those heterogeneous fi ndings, it is not clear if duration of GERD adds important information beyond frequency of GERD, and the model did not account for GERD duration. Another important limitation is that there were no recent estimates of the prevalence of daily GERD. Th e standardized incidence ratio of GERD for EAC was based on the summary odds ratio of published studies, and assumed to be the same at any age and for both sexes. Similarly, the prevalence of GERD was assumed to be the same at any age and for both sexes. Th e assumption regarding sex is generally supported, but the prevalence of GERD may actually peak in middle age ( 37 -39 ). If we had used age-specifi c prevalences of GERD with a peak in middle age, the eff ect would have been to decrease the estimate of the incidence of EAC in middle age, and / or increase the incidence in older ages without altering the general conclusions (data not shown).
Finally, the benchmark incidence of cancer was implied by the observed incidences at which screening is off ered for colorectal and breast cancer, but to our knowledge, the US Preventive Task Force does not utilize a specifi c threshold of cancer incidence for Men > 60 w/GERD (36%) Men < 60 w/GERD (22%) Men > 60 no GERD (19%) Men < 60 no GERD (11%) Women > 60 w/GERD (6%) Women > 60 no GERD (3%) Women < 60 w/GERD (2%) Women < 60 no GERD (1%) Figure 4 . Proportion of esophageal adenocarcinomas (EACs) arising from specifi c populations. There were 5,920 estimated annual cases of EAC in the United States among white non-Hispanics younger than 80 years. This chart displays the estimated proportions of those cancers arising from specifi c populations, stratifi ed by sex, age, and weekly gastroesophageal refl ux disease (GERD).
determining the age at which screening should be initiated. Other factors should also infl uence those guidelines, including the accuracy of screening, the fatality associated with the cancer, the biology of the cancer, and the safety and eff ectiveness of early treatment or preventive intervention ( 40 ) . If screening for EAC were particularly inexpensive, accurate, safe, and eff ective in comparison to screening for breast and colorectal cancers, then it might be reasonable to screen at incidences lower than the identifi ed benchmark. As it stands currently, however, screening for EAC would not appear to fi t any of those criteria ( 31 ) . Th erefore, screening should not be endorsed for individuals with predicted incidences of EAC lower than this benchmark. Whether screening should be off ered to individuals with predicted incidences greater than this benchmark (e.g., white men greater than 60 years of age with weekly GERD) cannot be directly addressed by the current study, but should also refl ect the other factors important in determining screening policy listed above.
In conclusion, we synthesized available data to estimate the absolute age-, sex-, and symptom-specifi c incidences of EAC, fi nding that the incidence is substantial in older white men with GERD, but when compared with the risk of other screened cancers, their risk of EAC is much lower. In other groups, such as younger men with GERD, or in women of any age with those symptoms, the absolute risk is very low, and does not warrant screening. While a group that is at reasonably elevated risk for EAC has been identifi ed, it still remains to be proven whether a screening program is eff ective and safe.
